Sökning: "anti-collagen antibodies"
Visar resultat 1 - 5 av 9 avhandlingar innehållade orden anti-collagen antibodies.
1. The role of anti-collagen type II antibodies in the pathogenesis and prognosis of rheumatoid arthritis
Sammanfattning : Rheumatoid arthritis (RA) which affects 0.5-1% of the world population and is characterised by joint erosions and presence of the autoantibodies anti-citrullinated protein antibodies (ACPA) and rheumatoid factor. LÄS MER
2. Anti-Collagen Type II Autoantibodies in an Acute Phenotype of Early Rheumatoid Arthritis
Sammanfattning : Rheumatoid arthritis (RA) is an autoimmune disease with systemic inflammatory features that primarily affects small peripheral joints. Type II collagen (CII), is the most abundant collagen type in joint cartilage. Antibodies against CII (anti-CII) are found in a subpopulation of RA patients. LÄS MER
3. The Role of Fc Gamma Receptors in Experimental Arthritis
Sammanfattning : Induction of collagen-induced arthritis (CIA), an animal model for human rheumatoid arthritis, is dependent on anti-collagen type II (CII) antibodies. The effector mechanism by which autoantibodies contribute to inflammatory reactions in autoimmune diseases is not well understood. LÄS MER
4. The Role of Fc gamma Receptors and Mast Cell Chymase in Autoimmune Arthritis
Sammanfattning : In autoimmune diseases such as rheumatoid arthritis (RA), self-reactive antibodies are present at high levels, which contributes to disease pathogenesis. The antibodies mediate their effect predominantly by binding to Fc gamma receptors (FcγR) on various leukocytes, such as monocytes, macrophages and mast cells, where FcγR ligation leads to cell activation. LÄS MER
5. Reactivity to collagen type II and C1q in rheumatic diseases
Sammanfattning : In rheumatoid arthritis (RA),other arthritides and in systemic lupus erythematosus (SLE) there is immunological reactivity to collagen type II (CII) and to complement component C1q. Parts of the CII and C1q molecules are structurally and immunologically related. LÄS MER